A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Ramesh K. Ramanathan, Chandra P. Belani, Deepti A. Singh, Michael Tanaka, Heinz Josef Lenz, Yun Yen, Hedy L. Kindler, Syma Iqbal, Jeff Longmate, Philip C. MacK, Georg Lurje, Regina Gandour-Edwards, Janet Dancey, David R. Gandara

研究成果: 雜誌貢獻文章同行評審

190 引文 斯高帕斯(Scopus)

摘要

Purpose: To evaluate the response to lapatinib, an inhibitor of epidermal growth factor receptors 1 and 2, in patients with advanced bilary tree cancer (BTC) and hepatocellular cancer (HCC). Methods: Lapatinib was dosed at 1,500 mg/day orally continuously. Results: Fifty-seven patients were accrued (BTC 17, HCC 40). Therapy was well tolerated. The response in BTC was 0% and in HCC was 5%. The progression free survival (PFS) for BTC and HCC patients was 1.8 (95% CI: 1.7-5.2) months and 2.3 (95% CI: 1.7-5.6) months. The median survival for BTC and HCC patients was 5.2 (95% CI 3.3-∞) months and 6.2 (95% CI: 5.1-∞) months. EGFR genotyping indicated HCC patients with <20 repeats have the lowest PFS. The occurrence of any skin rash significantly prolonged PFS and survival. Conclusions: Lapatinib was well-tolerated. There was evidence of activity in HCC, but therapy with lapatinib did not meet the predefined efficacy rate.

原文英語
頁(從 - 到)777-783
頁數7
期刊Cancer Chemotherapy and Pharmacology
64
發行號4
DOIs
出版狀態已發佈 - 九月 1 2009
對外發佈Yes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

指紋 深入研究「A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer」主題。共同形成了獨特的指紋。

引用此